Send us Feedback

Idera Pharmaceuticals (IDRA)
Analysis
SUMMARY
BULLS
BEARS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis
Benzinga  Jun 5  Comment 
Idera Pharmaceuticals (NASDAQ: IDRA) today announced that it has initiated dosing in a randomized, double-blind, placebo-controlled Phase 2 trial of IMO-8400 in patients with moderate to severe plaque psoriasis. IMO-8400, an antagonist of the...
Idera Pharmaceuticals, Inc. (IDRA) Posts Q1 Loss of 15c/Share
StreetInsider.com  May 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Idera+Pharmaceuticals%2C+Inc.+%28IDRA%29+Posts+Q1+Loss+of+15cShare/8339687.html for the full story.
Idera Pharma (IDRA) Issues Encouraging Update from IMO-3100 Phase 2
StreetInsider.com  May 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Idera+Pharma+%28IDRA%29+Issues+Encouraging+Update+from+IMO-3100+Phase+2/8315674.html for the full story.
Idera Pharmaceuticals Announces Closing of Common Share Offering
Benzinga  May 7  Comment 
Idera Pharmaceuticals (NASDAQ: IDRA) announced today the closing of its previously announced $16.5 million underwritten public offering of (i) 17,500,000 shares of common stock and related warrants to purchase up to 17,500,000 shares of common...
Idera Pharmaceuticals Prices 17.5M Share Offering at $0.50/Share
Benzinga  May 2  Comment 
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals (Nasdaq: IDRA) today announced the pricing of an underwritten public offering by Idera Pharmaceuticals of (i) for a combined public offering price of $0.50 per share...
Idera Pharma (IDRA) Completes IMO-8400 Phase 1 Dosing; 'No Objection' Received in Netherlands
StreetInsider.com  Apr 1  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Idera+Pharma+%28IDRA%29+Completes+IMO-8400+Phase+1+Dosing%3B+%27No+Objection%27+Received+in+Netherlands/8220616.html for the full story.
Idera Pharma (IDRA) Files $40M Common, Warrants Shelf
StreetInsider.com  Mar 11  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Idera+Pharma+%28IDRA%29+Files+%2440M+Common%2C+Warrants+Shelf/8173106.html for the full story.
Idera Pharmaceuticals, Inc. (IDRA) Narrows Q4 Loss to 24c/Share
StreetInsider.com  Mar 11  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Idera+Pharmaceuticals%2C+Inc.+%28IDRA%29+Narrows+Q4+Loss+to+24cShare/8172831.html for the full story.
Idera Pharmaceuticals (IDRA) to Offer Up to 9.08M Shares for Holders
StreetInsider.com  Jan 30  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Idera+Pharmaceuticals+%28IDRA%29+to+Offer+Up+to+9.08M+Shares+for+Holders/8045074.html for the full story.
UPDATE: Piper Jaffray Initiates Idera Pharmaceuticals at Overweight on Encouraging Data
Benzinga  Jan 3  Comment 
Piper Jaffray initiated overage on Idera Pharmaceuticals (NASDAQ: IDRA) with an Overweight rating and a $2 price target. Piper Jaffray commented, "Idera is developing IMO-3100, a TLR 7 and 9 antagonist, for the treatment of lupus. The company...




more ▼WIKI ANALYSIS
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_2/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800.
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


 




References

Retrieved from "http://www.wikinvest.com/stock/Idera_Pharmaceuticals_(IDRA)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki